Abstract
Skin has the capacity to produce and metabolize melatonin into biologically active metabolites. These metabolites exert phenotypic activities through receptor-dependent and receptor-independent action, including direct antioxidant activity, interaction with regulatory proteins, and regulation of mitochondrial function. They can act on G-protein-coupled melatonin receptors (MT1 and MT2) as well as nuclear aryl hydrocarbon receptor and peroxisome proliferator-activated receptor γ receptors. These metabolic pathways, together with receptor- and nonreceptor-mediated phenotypic activities of its intermediates, has been identified as a cutaneous melatoninergic system. Its pharmacological modulation and topical application of melatonin or its metabolites can be used to prevent and treat skin disorders and cutaneous aging.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call